Results 71 to 80 of about 84,576 (334)

Pulmonary endarterectomy in severe chronic thromboembolic pulmonary hypertension: the Toronto experience.

Annals of Cardiothoracic Surgery, 2022
Background Pulmonary endarterectomy (PEA) in severe chronic thromboembolic pulmonary hypertension (CTEPH) is associated with higher risks. However, recent evidence suggests that these risks may be mitigated with the use of extracorporeal membrane ...
M. de Perrot, K. McRae, L. Donahoe, Etienne Abdelnour-Berchtold, J. Thenganatt, J. Granton   +5 more
semanticscholar   +1 more source

Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension [PDF]

, 2018
Right ventricular (RV) function is the primary prognostic factor for both morbidity and mortality in pulmonary hypertension (PH). RV hypertrophy is initially an adaptive physiological response to increased overload; however, with persistent and/or ...
Bonnet, Sébastien, de Jesus Perez, Vinicio A., Frump, Andrea L., Lahm, Tim   +3 more
core   +1 more source

French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension

European Respiratory Journal, 2019
Aims To evaluate safety and efficacy of balloon pulmonary angioplasty (BPA) in a large cohort of patients with chronic thromboembolic pulmonary hypertension (CTEPH).
P. Brenot, X. Jaïs, Y. Taniguchi, C. Garcia Alonso, B. Gérardin, S. Mussot, O. Mercier, D. Fabre, F. Parent, M. Jevnikar, D. Montani, L. Savale, O. Sitbon, E. Fadel, M. Humbert, G. Simonneau   +15 more
semanticscholar   +1 more source

Selexipag for the treatment of chronic thromboembolic pulmonary hypertension

European Respiratory Journal, 2021
Background Treatment options for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) remain limited. Selexipag, an oral selective IP prostacyclin receptor agonist approved for pulmonary arterial hypertension, is a potential treatment option ...
T. Ogo, H. Shimokawahara, Hideyuki Kinoshita, S. Sakao, K. Abe, S. Matoba, Hirohiko Motoki, N. Takama, J. Ako, Y. Ikeda, S. Joho, H. Maki, Takahiro Saeki, T. Sugano, I. Tsujino, K. Yoshioka, N. Shiota, Shinichi Tanaka, Chieko Yamamoto, N. Tanabe, K. Tatsumi   +20 more
semanticscholar   +1 more source

Principles of pharmacological correction of pulmonary arterial hypertension [PDF]

, 2018
Prostanoids are a promising group of drugs for the treatment of pulmonary arterial hypertension (PAH), since they possess not only vasodilating, but also antiplatelet and antiproliferative actions.
Korokin, M. V., Korokina, L. V., Pokopejko, O. N., Zhernakova, N. I.   +3 more
core   +2 more sources

Non-invasive early exclusion of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the InShape II study

Thorax, 2021
Background The current diagnostic delay of chronic thromboembolic pulmonary hypertension (CTEPH) after pulmonary embolism (PE) is unacceptably long, causing loss of quality-adjusted life years and excess mortality.
G. Boon, Y. Ende-Verhaar, R. Bavalia, Lahassan H El Bouazzaoui, M. Delcroix, O. Dzikowska-Diduch, M. Huisman, K. Kurnicka, A. Mairuhu, S. Middeldorp, P. Pruszczyk, D. Ruigrok, P. Verhamme, H. Vliegen, A. Vonk Noordegraaf, J. Vriend, F. Klok   +16 more
semanticscholar   +1 more source

Microvascular Health as a Key Determinant of Organismal Aging

Advanced Science, EarlyView.
This review spotlights the emerging field of vascular aging, providing a comprehensive and critical overview of the molecular processes and clinical manifestations of vascular dysfunction during aging. By combining basic angioscience concepts with a critical analysis of innovative pre‐clinical aging models and lifestyle interventions, it offers a ...
Mattia Cenciarini, Andrea Uccelli, Francesca Mangili, Myriam Grunewald, Simone Bersini   +4 more
wiley   +1 more source

Balloon pulmonary angioplasty: a treatment option for inoperable patients with chronic thromboembolic pulmonary hypertension

Frontiers in Cardiovascular Medicine, 2015
In chronic thromboembolic pulmonary hypertension, stenoses or obstructions of the pulmonary arteries due to organized thrombi can cause an elevation in pulmonary artery resistance, which in turn can result in pulmonary hypertension.
Aiko eOgawa, Hiromi eMatsubara
doaj   +1 more source

Clinical–radiological–pathological correlation in chronic thromboembolic pulmonary hypertension

European Respiratory Review, 2023
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and potentially life-threatening complication of acute pulmonary embolism. It is characterised by persistent fibro-thrombotic pulmonary vascular obstructions and elevated pulmonary artery ...
Tom Verbelen, Laurent Godinas, Peter Dorfmüller, Deepa Gopalan, Robin Condliffe, Marion Delcroix   +5 more
doaj   +1 more source

Association of inferior vena cava filter placement for venous thromboembolic disease and a contraindication to anticoagulation with 30-day mortality [PDF]

, 2018
Importance: Despite the absence of data from randomized clinical trials, professional societies recommend inferior vena cava (IVC) filters for patients with venous thromboembolic disease (VTE) and a contraindication to anticoagulation therapy.
Brown, David L, Novak, Eric, Saeed, Mohammed J, Turner, Tyson E   +3 more
core   +1 more source